Navigation Links
Misonix, Inc. Announces Fourth Quarter and Fiscal Year 2013 Financial Results

FARMINGDALE, N.Y., Sept. 24, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the fourth quarter and fiscal year 2013 ended June 30, 2013.

Highlights for the quarter and the fiscal year included:

  • BoneScalpel revenue for the fiscal year 2013 increased 33% to $6.3 million when compared to fiscal 2012.
  • BoneScalpel units sold or placed increased to 165 units in fiscal 2013 from 121 units in fiscal 2012. Placed units in the United States were 38 units in fiscal 2013 compared to 11 units in fiscal 2012.
  • BoneScalpel disposable revenue increased 65% to $4 million in fiscal 2013 from $2.4 million in fiscal 2012.
  • SonicOne® revenue increased 43% to $1.9 million in fiscal 2013; units increased to 46 units in fiscal 2013 vs. 23 units in fiscal 2012.
  • SonicOne disposable revenue increased 115% to $315,000 in fiscal 2013.
  • SonaStar® revenue decreased 9.7% to $5.3 million in fiscal 2013.
  • Revenue from the BoneScalpel, SonicOne and SonaStar increased 13.1% to $13.5 million for the fiscal year 2013 compared to $11.9 million for fiscal 2012.
  • Received regulatory approval in China to sell SonaStar and BoneScalpel.
  • BoneScalpel units placed in the 4th quarter fiscal 2013 were 17 units compared to 5 units in fiscal 2012.
  • BoneScalpel domestic disposables increased 167% in the 4th quarter fiscal 2013 to $339,000.
  • Full-year 2013 Financial ResultsNet sales decreased 5% to $14.8 million for the full year ended June 30, 2013, as sales from legacy products continue to trail off as they approach end of life.  This compares with fiscal year 2012 revenue of $15.7 million. BoneScalpel revenue for the full year increased 33% to $6.3 million compared to $4.8 million in the previous year.  SonicOne revenue increased 43% in fiscal 2013 to $1.9 million compared to $1.3 million in fiscal 2012.  SonaStar revenue decreased 9.7% in fiscal 2013 to $5.3 million from $5.9 million in fiscal 2012. 

    The financial results in fiscal 2013 included an additional $1.7 million investment in sales and marketing. Additionally, the Company recorded reserves totaling $850,000 against Anika and Soma inventory and the Soma minimum gross profit accrual of $440,000. 

    The Company reported a loss of $2.7 million or $.38 diluted earnings per share compared to net income of $366,000 or $.05 per diluted share in fiscal 2012.  Excluding the impact of the reserve from inventory, accrual from the Soma minimum gross profit and the increased investment in sales and marketing, the Company would have reported approximately $0.04 full-year diluted earnings per share.

    Fourth Quarter Fiscal 2013 Financial ResultsRevenue for the three months ended June 30, 2013 was $3.8 million, a 29% decrease when compared to $5.3 million for the same period in fiscal 2012.  BoneScalpel revenue was $1.5 million, SonaStar revenue was $1.4 million and SonicOne revenue was $430,000 for the fiscal fourth quarter 2013, a 14% decrease when compared to the results in fiscal 2012. 

    There were 17 BoneScalpel units placed during the fourth quarter fiscal 2013 compared to 5 BoneScalpel units placed during fiscal 2012.  BoneScalpel domestic disposable sales increased 167% during the fourth quarter fiscal 2013 compared to the same period in fiscal 2012.

    The Company reported a net loss of $1.5 million or $.22 diluted per share compared to net income of $445,000 or $.06 earnings per share in fiscal 2012.  The Company recorded during its fourth fiscal quarter 2013 reserves of $850,000 million for the Anika and Soma inventory and the minimum gross profit requirement on the Soma product of $188,000.

    Michael A. McManus, Jr., President and CEO, stated, "Our flagship BoneScalpel, SonicOne and SonaStar products did very well in fiscal 2013. BoneScalpel and SonicOne did particularly well with solid double-digit growth in both the U.S. and internationally. As expected, revenue from our legacy products including the AutoSonix® and the LySonix® continue to trail off as they approach end of life status.  For the year these products were down $2.4 million.  Excluding legacy products, revenue from our core medical devices increased by 13% in a difficult selling environment.  Our products continue to be well accepted by the surgical community around the world."

    "The present healthcare procurement environment makes it more attractive for us to consign our products in the U.S. in conjunction with a commitment to purchase a set number of disposables," continued Mr. McManus. "This sales strategy results in lower early revenues but sets the stage for more consistent recurring revenue growth, which generate higher margins, in the future. In that regard, we look to expand the number of instruments placed in the field as our lead indicator for growth. More units in the field will yield greater recurring revenue at higher margins."

    "During fiscal 2013 we announced that the BoneScalpel was finally approved for sale in China and we are very excited about the potential for the product in that new market in the coming years.  We also continued investment in the marketing and sales of our products worldwide during the fiscal year.  In that regard, we hired Scott Ludecker as our VP of Worldwide Sales with the goal of upgrading our worldwide sales team and driving more consistent revenue growth.  The number of trained distributors both domestically and internationally was expanded. We added line extensions in blades, participated in the production of six clinical studies, conducted an increasing number of cadaver training labs and continued active participation in professional shows and conferences worldwide. All in all, fiscal 2013 was a solid foundational year that sets the stage for improving operational and financial results in the coming years," concluded Mr. McManus.

    Conference Call:
    The Company has scheduled a conference call today, Tuesday, September 24, 2013, at 4:30 pm ET to review the results. Interested parties can access the conference call by dialing (877) 317-6789 or (412) 317-6789 or can listen via a live Internet webcast, which is available in the Investor Relations section of the Company's website at

    A teleconference replay of the call will be available for three days at (877) 344-7529 or (412) 317-0088, confirmation # 10033492. A webcast replay will be available in the Investor Relations section of the Company's website at for 30 days. 

    About Misonix
    Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at

    Safe Harbor Statement
    With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships. Investor Relations Contacts:Misonix Contact: Lytham Partners, LLCRichard Zaremba Robert Blum, Joe Dorame, Joe Diaz631-694-9555

    mson@lythampartners.comFinancial Tables to Follow MISONIX, INC. And Subsidiaries Consolidated Balance SheetsUnauditedJune 30, 2013June 30, 2012AssetsCurrent Assets:  Cash and cash equivalents$5,806,437$6,273,015  Accounts receivable, less allowancefor doubtful accounts of $214,641 and$155,739, respectively2,974,6413,158,084  Inventories, net4,034,4774,380,841  Prepaid expenses and other current assets387,371306,691  Note receivable-198,117Total current assets13,202,92614,316,748Property, plant and equipment, net1,326,586891,822Goodwill1,701,0941,701,094Intangible and other assets1,129,3211,403,173Total assets$17,359,927$18,312,837Liabilities and stockholders' equityCurrent liabilities:  Accounts payable$2,208,999$1,507,695  Accrued expenses and other current liabilities1,276,9631,074,932Total current liabilities3,485,9622,582,627Deferred income72,934117,147Deferred lease liability23,81122,996Total liabilities3,582,7072,722,770Commitments and contingenciesStockholders' equity:  Capital stock, $0.01 par value - shares authorized 20,000,000, 7,233,884 and  7,082,920 shares issued and 7,156,324 and 7,005,360 shares  outstanding, respectively72,33970,829  Additional paid-in capital26,989,55926,132,951  Accumulated deficit(12,873,685)(10,202,720)  Treasury stock, at cost, 77,560 shares(410,993)(410,993)Total stockholders' equity13,777,22015,590,067Total liabilities and stockholders' equity$17,359,927$18,312,837 

     MISONIX, INC. And SubsidiariesCondensed Consolidated Statements of OperationsUnauditedThree Months EndedTwelve Months EndedJune 30,June 30,2013


    2012Net sales



    $15,678,000Cost of goods sold



    6,467,126Gross profit



    9,210,874Selling expenses



    5,031,831General and administrative expenses



    4,376,554Research and development expenses



    1,292,225Total operating expenses



    10,700,610(Loss) income from operations



    (1,489,736)Total other income



    686,189(Loss) income from continuing operations before  income taxes



    (803,547)Income tax (benefit) expense



    (194,782)Net (loss) income from continuing operations



    (608,765)Net (loss) income from discontinued operations, net of tax



    975,090Net (loss) income 



    $366,325Net (loss) income per share from continuing operations-Basic



    ($0.09)Net (loss) income per share from discontinued operations-Basic



    0.14Net (loss) income per share-Basic



    $0.05Net (loss) income per share from continuing operations-Diluted



    ($0.09)Net (loss) income per share from discontinued operations-Diluted



    0.14Net (loss) income per share-Diluted



    $0.05Weighted average common shares-basic



    7,001,930Weighted average common shares-diluted




    SOURCE Misonix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix, Inc. Announces the Grant of Patent by the United States Patent and Trademark Office
    2. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
    3. Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
    4. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
    5. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
    6. Positron Announces Reverse Stock Split and Registration as a Delaware Corporation
    7. GenVec Announces Dismissal Of Class Action Lawsuit
    8. Elekta Announces Monaco 5.0 -- Comprehensive Radiation Treatment Planning Capabilities Brought Together in One System
    9. Harwood Feffer LLP Announces Investigation of Transcept Pharmaceuticals, Inc.
    10. OPTIMIZERx Corporation Announces the Resignation of the Companys Current CEO & Chairman Mr. Shadron L. Stastney
    11. Abaxis Announces Management Transition
    Post Your Comments:
    (Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
    (Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
    (Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
    Breaking Medicine Technology:
    (Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
    (Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
    (Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
    (Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
    (Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
    Breaking Medicine News(10 mins):